<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide has been approved by the US Food and Drug Administration for the treatment of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with an interstitial deletion of the long arm of chromosome 5 and, more recently, in combination with <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> for <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> in patients who received at least one prior therapy </plain></SENT>
<SENT sid="1" pm="."><plain>This discussion examines several clinically relevant, practical considerations regarding dosing, monitoring, follow-up evaluation, adverse events, and available support for lenalidomide recipients and their prescribing physicians in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> setting </plain></SENT>
</text></document>